SCHEMBL4625003

SCHEMBL4625003

COc1ccccc1Oc1ccc2cc(C(C)C(NC(=O)c3c(Cl)cccc3Cl)C(=O)O)ccc2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.41
ITGB1 P05556 6/20 0.40
ITGAV P06756 1/20 0.40
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ITGA4 P13612 5/20 0.37
GHSR Q92847 1/20 0.37
PDE4D Q08499 1/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
PIK3CD O00329 1/20 0.35
PIK3R2 O00459 1/20 0.35
PIK3CG P48736 1/20 0.35
TACR3 P29371 1/20 0.35
MAPT P10636 1/20 0.35
PYGL P06737 1/20 0.35
ITGB7 P26010 4/20 0.35
CCKAR P32238 2/20 0.35
CCKBR P32239 2/20 0.35
USP2 O75604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6142438 0.89 ITGB1 (0.42) ITGB1ITGAVITGA4GHSRMAPT
SCHEMBL4624866 0.86 ITGB1 (0.52) SMN1; SMN2ITGB1ITGAVMEN1KMT2A
SCHEMBL4626488 0.81 ITGB1 (0.64) ITGB1ITGAVITGA4ITGB7
SCHEMBL4624055 0.80 ITGA4 (0.51) SMN1; SMN2ITGB1MEN1KMT2AITGA4
SCHEMBL3319927 0.80 ITGB1 (0.62) ITGB1ITGAVMEN1KMT2AITGA4
SCHEMBL4624998 0.77 ITGB1 (0.54) ITGB1ITGAVITGA4ITGB7
SCHEMBL4624246 0.75 ITGB1 (0.64) ITGB1ITGAVITGA4ITGB7
SCHEMBL1028110 0.75 ITGB1 (0.55) ITGB1ITGAVMEN1KMT2AITGA4
SCHEMBL4625005 0.73 ITGB1 (0.40) SMN1; SMN2ITGB1ITGAVMEN1KMT2A
SCHEMBL4627182 0.72 ITGB1 (0.54) ITGB1ITGAVITGA4ITGB7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501801-B1 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES UCB PHARMA SA (BE) 2008-01-23 EP disclosed